🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Balaxi Pharmaceuticals Limited BALAXI NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://balaxipharma.in
Company Profile ↓
₹25.37
-47.77% 1Y
Mkt Cap₹140.06 Cr
P/E56.38
P/B0.52
52W High₹48.75
52W Low₹15.67
Book Value₹45.12
EPS (TTM)₹0.45

Company Overview

Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in India, Africa, and Latin America. The company offers pharmaceutical products across various therapeutic areas, including antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpaste. The company was formerly known as Balaxi Ventures Limited and changed its name to Balaxi Pharmaceuticals Limited in October 2020. The company was incorporated in 1942 and is headquartered in Hyderabad, India. Balaxi Pharmaceuticals Limited is a subsidiary of Balaxi Overseas Private Limited.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.23.

Recent Developments

  • Mar 2026 Revenue of ₹270.17 Cr (-7.7% YoY); net profit ₹1.42 Cr.
  • Trailing 12 Months Year-on-year growth — revenue -7.3%, earnings -92.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR -7.1%, profit CAGR -68.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-7.05%
1 Year:-7.30%

Compounded Profit Growth

5 Years:-68.64%
1 Year:-92.90%

Stock Price Performance

1 Year:-47.77%
6 Months:+39.70%
3 Months:+4.75%
1 Month:+4.83%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 29% of range
₹15.67 ₹48.75
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)64.37 · Neutral
Price Performance
1M+4.83%
3M+4.75%
6M+39.70%
1Y-47.77%
Valuation vs Sector

P/E of 56.38 is above the sector median of 40.02 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Trading at a high P/E of 56.4.
  • Revenue declined at -7.1% CAGR over 5 years.
  • Earnings shrank at -68.6% CAGR over 5 years.
  • Trading 48.0% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
56.38
Industry PE
40.02
Forward P/E est.
112.76
PEG Ratio
-
Book Value
₹45.12
Price to Book
0.52
P/S
0.48
EV/EBITDA
20.66
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-7.05%
Profit 5Y
-68.64%
Revenue (YoY)
-7.30%
Earnings (YoY)
-92.90%

Profitability & Returns

ROCE
3.35%
ROE
0.59%
ROA
1.23%
Profit Margin
0.52%
Op Margin
-0.74%
Gross Margin
44.16%
EPS (Latest Qtr)
₹0.11
EPS (TTM)
₹0.45

Balance Sheet & Liquidity

Debt/Equity
0.23
Quick Ratio
2.42
Current Ratio
4.04
Debt
₹57.65 Cr
Total Assets
₹337.03 Cr
Current Assets
₹251.43 Cr
Working Capital
₹189.27 Cr

Ownership

Promoter Holding
-
Chg in Prom Hold
-
FII / Inst Holding
-
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹140.06 Cr
Total Revenue (TTM)
₹270.17 Cr
EBITDA
₹8.53 Cr
Free Cash Flow
₹-63.47 Cr
Operating Cash Flow
₹-4.50 Cr
Shares Outstanding
₹5.52 Cr
Gross Margin
44.16%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 BALAXI Balaxi Pharmaceuticals Limited NSEPHARMA 25.37 56.38 ₹140.06 Cr 0.00% 3.35% 0.59% -7.05% -68.64%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,895.00 37.64 ₹4.55 L Cr 0.85% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,315.00 84.60 ₹2.47 L Cr 0.31% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,914.00 78.62 ₹1.87 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.23% 19.20% 20.48% 14.85% 33.34%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 688.00 237.24 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,156.90 23.10 ₹1.16 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 33.25 ₹1.12 L Cr 0.94% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 90.86 ₹99,417.45 Cr 0.12% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -76.27 Cr70.74 Cr56.18 Cr72.54 Cr70.71 Cr
Cost of Revenue -39.56 Cr39.56 Cr29.03 Cr41.74 Cr40.55 Cr
Gross Profit -36.71 Cr31.18 Cr27.15 Cr30.81 Cr30.16 Cr
Operating Expenses -24.62 Cr27.50 Cr26.46 Cr28.28 Cr30.69 Cr
Operating Income -12.09 Cr3.69 Cr68.41 L2.53 Cr-52.48 L
EBITDA -10.86 Cr2.37 Cr2.75 Cr3.19 Cr3.04 Cr
Interest Expense -73.56 L1.01 Cr89.22 L1.02 Cr98.99 L
Pretax Income -9.66 Cr90.34 L1.38 Cr1.61 Cr1.40 Cr
Tax Provision -1.03 Cr61.33 L1.17 Cr1.30 Cr78.97 L
Net Income -8.64 Cr29.01 L20.90 L30.50 L61.28 L
Diluted EPS -1.560.050.040.060.11

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -336.43 Cr241.29 Cr292.56 Cr270.17 Cr
Cost of Revenue -202.42 Cr128.68 Cr165.70 Cr150.88 Cr
Gross Profit -134.02 Cr112.61 Cr126.86 Cr119.30 Cr
Operating Expenses -78.35 Cr66.83 Cr91.54 Cr112.92 Cr
Operating Income -55.66 Cr45.79 Cr35.32 Cr6.38 Cr
EBITDA -59.17 Cr5.79 Cr33.50 Cr11.35 Cr
Interest Expense -50.00 L1.68 Cr2.93 Cr3.90 Cr
Pretax Income -56.92 Cr2.02 Cr28.67 Cr5.29 Cr
Tax Provision -10.96 Cr4.40 Cr3.60 Cr3.88 Cr
Net Income -45.96 Cr-2.39 Cr25.07 Cr1.42 Cr
Diluted EPS 9.539.08-2.324.54-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -239.67 Cr258.34 Cr310.34 Cr337.03 Cr
Current Assets -193.51 Cr210.17 Cr242.77 Cr251.43 Cr
Cash & Equivalents -28.22 Cr62.29 Cr39.40 Cr14.56 Cr
Inventory -105.02 Cr82.17 Cr78.48 Cr83.48 Cr
Receivables -52.28 Cr55.71 Cr110.80 Cr136.10 Cr
Total Liabilities -56.79 Cr56.98 Cr78.61 Cr87.95 Cr
Current Liabilities -53.13 Cr54.20 Cr54.53 Cr62.16 Cr
Long Term Debt -86.97 L021.24 Cr22.35 Cr
Total Debt -13.31 Cr19.40 Cr53.43 Cr57.65 Cr
Total Equity -182.88 Cr201.36 Cr231.74 Cr249.08 Cr
Shares Outstanding -5.09 Cr5.45 Cr5.52 Cr5.52 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -6.08 Cr4.87 Cr-35.00 Cr-4.50 Cr
Investing Cash Flow --10.57 Cr-1.05 Cr-21.76 Cr-20.78 Cr
Financing Cash Flow -25.51 Cr30.25 Cr33.88 Cr43.98 L
Capital Expenditure --14.98 Cr-1.57 Cr-21.76 Cr-42.85 Cr
Free Cash Flow --8.90 Cr3.30 Cr-56.77 Cr-47.35 Cr
Net Change in Cash -21.02 Cr34.07 Cr-22.89 Cr-24.84 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -39.8%46.7%43.4%44.2%
Operating Margin % -16.5%19.0%12.1%2.4%
Net Margin % -13.7%-1.0%8.6%0.5%
ROE % -25.1%-1.2%10.8%0.6%
ROCE % -29.8%22.4%13.8%2.3%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BALAXI

Google News Fri, 04 Sep 2026

Balaxi Pharmaceuticals Ltd. Key Financial Ratios – Valuation, Profitability & More - Value Research

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPMWkta21hYkZVVW1WNnZIMXcwYmxLVTFiVVBWUHJDcEJYNExfRVhMdV9qR0RMamZkUWpPc095V3o1NzhPa01Pdm44N3ZkcFdfbEFnaEhzcUhxS1VIQjJqRFY1YzJVV0RJUmkzVE05SlJuVHcyVWo4M1k1eVpGX0thSGRDTnY3bFVrT2FUQk…

Google News Wed, 31 Dec 2025

Balaxi Pharmaceuticals Limited (NSE:BALAXI) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxPSXpjVTNCTHVBT3hQcHpxU0MzYmhCNFVJa3R3MnpKRGRXMElPcjdId3I5ZEgzY0pQTXdJNWhaMUp0azlWSnQxNnd1aGJXbTNGUGY1QXNLYUFwRTVaLUVyN092TzJCT1N4cElzZkh3ZHEwQi1Cbk1kbDBjTnh5SzRRMmxzOGc5MzRxalFSaT…

Google News Wed, 02 Sep 2026

Balaxi Pharmaceuticals Share Price News and Valuation Check - Univest

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNR2x3SVNEbnpYazFjZ3VCMTdla0pUR3dTM2gwa2pqOUoxNGFoUnpGTzJ6alVvam9OaEhoZmt4cEJaaWJpc3pLbXJxTHZqQkRLN0JYWS05ZUJjWVJPMnhfRFVzYURac3dUTHdnM1lJdWlpY3JTSnpWWk14VVFKY1BFSFZpRExXR1RPQjhZ?o…

Google News Mon, 10 Aug 2026

Balaxi Pharma Standalone June 2026 Net Sales at Rs 15.58 crore, down 6.73% Y-o-Y - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxQTEFkYjcxYkhjMDRJXy1qVlZxRWYySGZFVDNJNERVUjk0UFBKeU92VkIyN0VLcWtCcHJGaTcyVm5YUHpHOHVsczZLekMyLVg3NXJtSXFjelZnWGdZZkJFdzkwU294OFFwLTNwUUw4NGloT0dER0o5T2VzMjFQbnBrV05OdVFsdkRDdnFUSk…

Google News Fri, 03 Jul 2026

BALAXI.NS Mar 2026 Earnings: Modest EPS of ₹0.03 as Revenue Holds Steady - Annual Report - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOQjlPN1FXUXRuU2ViUkpGMTNnamZ4VUlSQWItWGtOVnl0VnZwMlVtU20tdU56R1VyaXk0alNPdlpkQWNTeEhCbEJTZGRUY0xkMXRNRFZKQ0dKUXdUS0NjMU96MVJwc3dHVHQ5Y2l5N2tTR2VhRzdpV3NLVkd1eVhFOF9PLWdVRzZmNE1MRn…

Google News Mon, 31 Aug 2026

Balaxi Pharmaceuticals Ltd. Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxNR0pVZ3lPNmEyRG9DNjljd2RmTk5JQjk2cEF3SXZJSXUzaHVraG5INXh5NFI5U0NVNTdNY3R0V2ljZndXdVM0bk5NMDZSdkg3ck1ZR2NwSWhhVVRkT1NFcXEtNjVWLWE5OU9BYWpTNjBDcFFMYm1aamhlOFJGRXZiN2ItWGxPdXYyMVZXbW…

BALAXI — Frequently Asked Questions

What is the current share price of Balaxi Pharmaceuticals Limited (BALAXI)?

As of 2026-09-20 09:43 IST, Balaxi Pharmaceuticals Limited (BALAXI) trades at ₹25.37 on NSE. Its 52-week range is ₹15.67 to ₹48.75.

What is the market capitalisation of BALAXI?

Balaxi Pharmaceuticals Limited (BALAXI) has a market capitalisation of ₹140.06 Cr on NSE.

What is the P/E ratio of BALAXI?

BALAXI trades at a trailing price-to-earnings (P/E) ratio of 56.38. The industry average P/E is 40.02. Its price-to-book (P/B) ratio is 0.52.

What is the return on equity (ROE) of BALAXI?

BALAXI has a return on equity (ROE) of 0.59%. Its return on capital employed (ROCE) is 3.35%.

Is BALAXI a good stock to buy?

This page provides a data-driven analysis of Balaxi Pharmaceuticals Limited (BALAXI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space